10X Research: Retail investors have lost $17 billion buying stocks of digital asset treasury companies
Jinse Finance reported, citing Bloomberg, that Singapore-based cryptocurrency research institution 10X Research released a report indicating that retail investors who purchased stocks of digital asset treasury companies have suffered losses amounting to $17 billion. Analysts pointed out that US-listed companies choosing some small-cap tokens as treasury reserves may expose retail investors buying company stocks to risk if market sentiment shifts. Bloomberg provided the following examples in the article: 1. Tharimmune raised $545 million to establish a Canton Coins treasury, pricing the Canton token at $0.2 during fundraising, but the current market price of the token is $0.11; 2. Alt5 Sigma raised $1.5 billion to establish a WLFI treasury, pricing the WLFI token at $0.2 during fundraising, but the current market price of the token is $0.14; 3. Flora Growth raised $401 million to establish a 0G treasury, pricing the 0G token at $3 during fundraising, but the current market price of the token is $1.2.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
Market Is Primed for a ‘Face Ripper' Rally Thanks to Four Ingredients Says Tom Lee
